Medicinal complex for treating type 2 diabetes and diabetic dyslipidemia

A pharmacy and dosage form technology, applied in the field of combined preparations of type 2 diabetes and dyslipidemia, can solve problems such as increasing the risk of cardiovascular disease, and achieve the effect of improving drug compliance and treating dyslipidemia

Inactive Publication Date: 2019-07-09
LG CHEM LTD
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Hypertension and dyslipidemia are also major contributors to cardiovascular disease, thereby significantly increasing the risk of cardiovascular disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal complex for treating type 2 diabetes and diabetic dyslipidemia
  • Medicinal complex for treating type 2 diabetes and diabetic dyslipidemia
  • Medicinal complex for treating type 2 diabetes and diabetic dyslipidemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Embodiment 1: the preparation of fixed dosage

[0036] According to the composition of Table 1, fixed-dose combinations of 3 formulations were prepared, in which the content of rosuvastatin was different.

[0037] [Table 1]

[0038]

[0039] 1) Supertab 21AN: lactose anhydrous

[0040] 2) Prosolv SMCC 50: Silicified microcrystalline cellulose

[0041] 3) DI-TAB: Calcium hydrogen phosphate dihydrate

[0042] 4) Kollidon VA64: vinylpyrrolidone-vinyl acetate copolymer

Embodiment 2

[0043] Embodiment 2: the preparation of bilayer tablet

[0044] According to the composition of Table 2, two-layer tablets of 3 kinds of preparations were prepared, and in the 3 kinds of preparations, the content of rosuvastatin was different. The preparation method is presented in Table 3.

[0045] [Table 2]

[0046]

[0047]

[0048] 1) Flowlac 100: lactose monohydrate

[0049] 2) DI-TAB: Calcium hydrogen phosphate dihydrate

[0050] 3) Kollidon VA63: vinylpyrrolidone-vinyl acetate copolymer

[0051] [table 3]

[0052]

[0053]

Embodiment 3

[0054] Embodiment 3: stability test

[0055] The stability test of the bilayer tablet formulation prepared in Example 2 was carried out under accelerated conditions (40° C., 75% humidity) for 6 months. The results are presented in Table 4.

[0056] [Table 4]

[0057]

[0058] DP-IMP-1:

[0059] 2-[(2S)-6,6-Difluoro-2,3,5,6,7,8-hexahydroimidazo[1,2-a]pyridin-2-yl]-1-[2,4 -Bis(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-7-yl]-1-ethanone

[0060] DP-IMP-2:

[0061] 2,4-bis(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-8-one

[0062] DP-IMP-3:

[0063] (3S)-3-amino-4-(5,5-difluoro-2-oxopiperidinyl)-1-[8-hydroxy-2,4-bis(trifluoromethyl)-5,6, 7,8-Tetrahydropyrido[3,4-d]pyrimidin-7-yl]butan-1-one tartrate

[0064] 5-oxo:

[0065] Bis(6E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R)-3-hydroxy -5-oxohept-6-enoic acid

[0066] Lactone:

[0067] N-(4-(4-fluorophenyl)-5-(1E)-2-[(2S,4R)-4-hydroxy-6-oxotetrah...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a medicinal complex for effectively treating type 2 diabetes and dyslipidemia of diabetic patients, more specifically, the present invention provides a medicinal complex comprising a peptidase IV inhibitor gemigliptin or a pharmaceutically acceptable salt thereof, and a HMG-CoA reductase inhibitor rosuvastatin or a pharmaceutically acceptable salt thereof, to effectively control blood sugar levels and improve cardiovascular disease risk factors.

Description

technical field [0001] The present invention relates to a combined preparation for the effective treatment of type 2 diabetes and dyslipidemia in diabetic patients. More specifically, the present invention provides a combined preparation comprising gemagliptin or a pharmaceutically acceptable salt thereof as a dipeptidyl peptidase IV inhibitor and rhodium as an HMG-CoA reductase inhibitor. Suvastatin or a pharmaceutically acceptable salt thereof can effectively control blood sugar and improve risk factors of cardiovascular diseases. Background technique [0002] In 2011, the International Diabetes Federation (IDF) estimated that 366 million people worldwide had diabetes. In addition, according to IDF, 80% of diabetic patients live in low- and middle-income countries, and about 36% of diabetic patients live in the Western Pacific region including Korea. However, considering that approximately 183 million people have undiagnosed diabetes, the IDF estimates that there are mor...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/519A61K31/505A61K31/225
CPCA61K31/225A61K31/505A61K31/519A61K2300/00A61P3/10A61P31/06
Inventor 朴基淑尹慧真郑钟赫金成垣金志玧刘锡澈金利宣安在淳
Owner LG CHEM LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap